Releases - Allenex AB

View:
 

Found press releases

 

Meet the new Allenex in Stockholm, May 15 at 3 pm

5/10/2012 8:16 AM EST
The new Allenex, as a pure transplantation company, is presenting at Avanza Bank stock market day.
”Now that our new Allenex in its new role as a pure transplantation company has reported its first quarterly operating profit, I greet old and new shareholders welcome to see and hear my presentation of our new Allenex. We sell our leading and new products on a growing market. Welcome to Avanza Bank stock market...

Allenex turn to positive operating result in first quarter

5/8/2012 8:02 AM EST
Allenex has today issued the Interim report January - March 2012

· Net sales for the quarter were SEK 30.0 million (20.5), an increase of 46 percent year on year. (Olerup GmbH was not a part of the group in the first quarter 2011.)
· Operating income (EBIT) for the quarter was SEK 3.0 million (-3.1).
· Operating margin for the quarter was 10 (-15) percent.
· Result after tax for the quarter was SEK -0.4...

Annual Report 2011

5/8/2012 4:15 AM EST
Allenex annual report for 2011 is now available at www.allenex.com
Allenex annual report for 2011 is now available at www.allenex.com, and can be downloaded in full by link below.

Allenex is a life science-company that develop, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54...

Correction: Allenex sells its holding in Pharmacolog

4/27/2012 8:21 AM EST
Allenex sells its holding in Pharmacolog i Uppsala AB to some of the other owners in the company for sek 300.000
Correction: corrected time of publishing.

Pharmacolog is a company that develop systems to control content and concentration in liquid drugs, used mainly in chemotherapy for cancer treatment. Pharmacolog is still in an early phase and the company presently has products in development and validation....

Allenex sells its holding in Pharmacolog

4/27/2012 7:02 AM EST
Allenex sells its holding in Pharmacolog i Uppsala AB to some of the other owners in the company for sek 300.000
Pharmacolog is a company that develop systems to control content and concentration in liquid drugs, used mainly in chemotherapy for cancer treatment. Pharmacolog is still in an early phase and the company presently has products in development and validation. Allenex have been a part-owner in the...

Allenex strengthens presence on the European transplantations market.

4/27/2012 2:41 AM EST
Holland and Belgium becomes direct sales markets for all Allenex products from May 1st 2012.
As a part of Allenex focus to build a global transplantation technology company with a strong sales and support organization the company now choose to sell directly to end customers in Holland and Belgium. The cooperation with the present distributor, Genome Products BV is terminated and Allenex will sell through its...

Year-end report 2011

2/23/2012 9:00 AM EST
For the fourth quarter, October - December

· Net sales for the quarter were SEK 27.5 million (20.0), an increase of 37.5 percent year on year. The quarter’s results included full sales figures from Olerup GmbH, which was consolidated into the group as of June 1, 2011.
· Operating loss (EBIT) for the quarter was SEK 76.0 million (-4.0). The results were impacted by the impairment of intangible assets of SEK 74.6...

Allenex Board of directors evaluates the mandatory public offer from Xenella Hol...

11/23/2011 2:10 PM EST
Godcup 7154 AB, undergoing name change to Xenella Holding AB (”Xenella”) has under the rules on mandatory public offers, on 23 November 2011, announced a public cash offer,  to the shareholders of Allenex AB (publ) (”Allenex”), to sell all shares in Allenex to Xenella (the “Offer”). Xenella offers SEK 1.50 in cash for each share. The Offer does not include convertible instruments issued by Allenex. Xenella’s press...

Interim report January - September 2011

11/16/2011 7:00 AM EST
For the third quarter July - September

· Net sales for the quarter were SEK 26.3 million (19.1), an increase of 37.7 percent. Third quarter results include sales from Olerup GmbH, which from June 1 is a part of the group.
· Operating loss (EBIT) for the quarter was SEK 0.2 million (-8.0).
· Loss after tax was SEK 59.3 million (-8.4). The results were impacted with the write down of the value of the associated...

Olerup Inc presented the extended HLA typing portfolio at this year’s ASHI

10/26/2011 8:00 AM EST
At the recently held ASHI meeting in New Orleans, Allenex subsidiary Olerup SSP and Conexio presented the now extended HLA typing portfolio distributed in the US by Olerup Inc. The focus of the symposium was the recently signed global distribution agreement between Conexio and Olerup SSP. Through the agreement Olerup SSP acquired the distribution and marketing rights for the Conexio SBT Resolver™ product line which...

Allenex AB

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical ...

View more


  CONTACT